Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | THRB | P10828 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CD69 | Q07108 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20017046 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL13096289 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL22058769 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL22059479 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL23323248 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL21029771 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL23332629 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL23719677 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL20990354 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL19767510 | 1.00 | ALDH1A1 (0.78) | ALDH1A1THRBMAPK1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119744182-A | Antibody drug conjugates comprising a mutant Fc region | 第一三共株式会社 | 2025-04-01 | — | — | CN | disclosed |
| CN-118804983-A | Method for producing Fc-containing molecule | 第一三共株式会社 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024048490-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING MUTANT FC REGION | 第一三共株式会社 | 2024-03-07 | — | — | WO | disclosed |
| WO-2023167238-A1 | METHOD FOR PRODUCING Fc-CONTAINING MOLECULE | 第一三共株式会社 | 2023-09-07 | — | — | WO | disclosed |
| US-11564989-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11564989-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | DCTD, ADCY8, ADCY3 | ALDH1A1 548/4885THRB 3835/4885MAPK1 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.